Evidence map›Paper›PMID 38051367›Full record

ArticleArchives of toxicology2024

Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries.

Inmaculada Medina-Cáliz, Judith Sanabria-Cabrera, Marina Villanueva-Paz, Lauryna Aukštikalnė, Camilla Stephens, Mercedes Robles-Díaz, José M Pinazo-Bandera, Miren García-Cortes, Isabel Conde, German Soriano and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. [Research advances on the role of eosinophils in acute liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. DRESS Syndrome Mimicking Postoperative Cholestasis: A Case Report.Clinical medicine insights. Case reports · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 5 countries.

Inmaculada Medina-Cáliz *Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Judith Sanabria-Cabrera *Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Marina Villanueva-Paz *Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Lauryna AukštikalnėInstitute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Camilla StephensServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Mercedes Robles-DíazServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
José M Pinazo-BanderaServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Miren García-CortesServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Isabel CondeCentro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
German SorianoCentro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Fernando BessoneHospital Provincial del Centenario, Rosario, Argentina.
Nelia HernandezHospital de Clínicas, Montevideo, Uruguay.
Vinicius NunesHospital Universitário Prof. Edgard Santos-UFBA, Salvador, Brazil.
Raymundo ParanáHospital Universitário Prof. Edgard Santos-UFBA, Salvador, Brazil.
M Isabel LucenaServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain. lucena@uma.es.ORCID 0000-0001-9586-4896
Raúl J Andrade *Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Hao Niu *Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Ismael Alvarez-Alvarez *Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de La Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESSpanish Clinical Research Network · ESComplexo Hospitalar Universitário Professor Edgard Santos · BRClínica Rementería · ESHospital de Clínicas · UYHospital Provincial de Rosario · ARHospital Universitari i Politècnic La Fe · ESInstituto de Investigación Biomédica de Málaga · ESLithuanian University of Health Sciences · LTUniversitat Autònoma de Barcelona · ES

Funding

Consejería de Salud y Consumo, Junta de Andalucía PEMP-0127-2020Consejería de Salud y Consumo, Junta de Andalucía PI-0310-2018Consejería de Salud y Consumo, Junta de Andalucía POSTDOC_21_00780European Cooperation in Science and Technology CA17112Instituto de Salud Carlos III CD20/00083Instituto de Salud Carlos III CD21/00198Instituto de Salud Carlos III CM21/00074Instituto de Salud Carlos III JR21/00066Instituto de Salud Carlos III PI19/00883Instituto de Salud Carlos III PI21/01248Instituto de Salud Carlos III PT20/00127Instituto de Salud Carlos III PY18-3364Instituto de Salud Carlos III UMA18-FEDERJA-194
6 · The paper itself

Abstract

Idiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n = 881). DILI-DRESS cases were younger (47 vs. 53 years, respectively; p = 0.042) and presented more frequently with cholestatic/mixed damage (p = 0.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04-1.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11-69.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.

Indexed as

Chemical and Drug Induced Liver InjuryCholestasisDrug Hypersensitivity SyndromeEosinophiliaAllopurinolAnticonvulsantsAntitubercular AgentsHumansLamotrigineProspective StudiesRegistriesAllopurinolAnticonvulsantsAntitubercular AgentsLamotrigineDrug-induced liver injuryDrug reaction with eosinophilia and systemic symptomsHepatotoxicityHypersensitivity featuresSevere cutaneous adverse reaction

Identifiers

PMID38051367
PMCPMC10761448
OpenAlexW4389347026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.